B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast-2030


Albany, NY -- (SBWIRE) -- 06/04/2020 -- B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast-2030

DelveInsight launched a new report on B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

1. The total incident cases of Non-Hodgkin Lymphoma (NHL) in the 7MM was 166,909 in 2017.

2. Among the 7MM, the highest Incident population of B cell-NHL was in the United States with 61,080 cases in 2017.

3. The most incident age-group for B-cell NHL among the 7MM was 65–74 years in 2017. Patients of age groups 55–64 years were observed to be the second-highest in 2017.

Key benefits of the report

1. B-Cell Non-Hodgkin Lymphoma market report covers a descriptive overview and comprehensive insight of the B-Cell Non-Hodgkin Lymphoma Epidemiology and B-Cell Non-Hodgkin Lymphoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. B-Cell NHL market report provides insights into the current and emerging therapies.

3. B-Cell Non-Hodgkin Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. B-Cell NHL market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the B-Cell Non-Hodgkin Lymphoma market.

Request for sample pages

"B-cell NHL market size was USD 6,114 million in the 7MM countries in 2017."

There are several treatment options for B-cell lymphoma, which include chemotherapy, radiation, and immunotherapy. The aforementioned B-cell lymphoma treatment modalities have been used, alone or in combination. The choice of treatment for B-cell lymphoma is dependent on the type of B-cell Lymphoma, symptoms, age, and how fast it is growing and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies.

Rituximab was the first mAb to be approved for the treatment of cancer and the first single-agent approved specifically for refractory B-cell low-grade NHL. Following its initial US FDA approval for low-grade NHL in 1997, it was approved for other subtypes of lymphoma, including DLBCL, CLL, and FL. In February 2002, the first radio-immunotherapeutic agent to receive approval by the FDA. Zevalin is indicated for the treatment of relapsed or low refractory grade, follicular, or transformed B-cell NHL.

The launch of the emerging therapies is expected to significantly impact B-Cell Non-Hodgkin Lymphoma treatment scenario in the upcoming years:-

Drugs covered
1. Tafasitamab
2. Lisocabtagene maraleucel (JCAR017)
3. Enzastaurin Hydrochloride (DB102)
4. Avelumab (Bavencio)
5. Umbralisib (TG-1202)
6. MBCART2019.1

And many others

The key players in B-Cell Non-Hodgkin Lymphoma market are:
1. MorphoSys AG
2. Bristol-Myers Squibb
3. Denovo Biopharma
4. Pfizer
5. Merck
6. TG Therapeutics
7. Miltenyi Biotec

And many others

Table of contents
1. Key Insights
2. Executive Summary of B-cell NHL
3. SWOT Analysis for B-cell NHL
4. B-cell NHL Patient Share of B-cell NHL at a Glance
5. B-cell NHL Market Overview at a Glance
6. B-cell Non-Hodgkin Lymphoma Disease Background and Overview
7. B-cell Non-Hodgkin Lymphoma Epidemiology and Patient Population
8. B-cell Non-Hodgkin Lymphoma Epidemiology Scenario: 7MM
9. United States Epidemiology
10. EU-5 Country-wise Epidemiology
10.1. Germany Epidemiology
10.2. France Epidemiology
10.3. Italy Epidemiology
10.4. Spain Epidemiology
10.5. United Kingdom Epidemiology
11. Japan Epidemiology
12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS)
13. Unmet Needs
14. B-cell Non-Hodgkin Lymphoma Marketed Products
14.1. Brukinsa (Zanubrutinib): BeiGene
14.2. Polivy (Polatuzumab vedotin): Hoffmann-La Roche
14.3. Venetoclax (ABT199): AbbVie and Roche
14.4. Kymriah (tisagenlecleucel): Novartis
14.5. Copiktra (Duvelisib): Verastem
14.6. Keytruda (Pembrolizumab): Merck Sharp & Dohme
14.7. Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences
14.8. Aliqopa (Copanlisib; BAY 80-6946): Bayer
14.9. Calquence (Acalabrutinib): AstraZeneca
14.10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
14.11. Zydelig (Idelalisib): Gilead Sciences
14.12. Gazyva (Obinutuzumab, GA-101): Genentech (Roche Group)
14.13. Revlimid (lenalidomide): Celgene Corporation
14.14. Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutica
14.15. Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals
14.16. Torisel: Pfizer
15. B-cell Non-Hodgkin Lymphoma Emerging Therapies
15.1. Key Cross
15.2. Tafasitamab (MOR208; formerly XmAb 5574): MorphoSys AG
15.3. Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb
15.4. Enzastaurin Hydrochloride (DB102): Denovo Biopharma
15.5. Avelumab (Bavencio): Pfizer/Merck
15.6. Umbralisib (TG-1202): TG Therapeutics
15.7. MBCART2019.1: Miltenyi Biotec
16. B-cell NHL: Seven Major Market Analysis
17. B-cell Non-Hodgkin Lymphoma Market Outlook: 7MM
18. United States Market Size
19. EU-5 Market Size
19.1. Germany Market Size
19.2. France Market Size
19.3. Italy Market Size
19.4. Spain Market Size
19.5. United Kingdom Market Size
20. Japan Market Size
21. Market Access and Reimbursement Scenario of B-cell NHL Therapies
22. Market Drivers
23. Market Barriers
24. Appendix
25. Disclaimer
26. DelveInsight Capabilities
27. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
SOURCE DelveInsight